Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,254.01
(
0.62%
)
US TECH 100
26,957.60
(
0.93%
)
Dow Jones
49,832.37
(
0.36%
)
Brent Oil
108.23
(
-1.93%
)
Bitcoin
78,189.09
(
2.44%
)
News Focus
News Focus
Post# of 257475
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122918
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 202845

Tuesday, 07/26/2016 10:16:06 AM

Tuesday, July 26, 2016 10:16:06 AM

Post# of 257475
The NASH arena is getting pruned. After the success of ICPT's phase-2 FLINT study a couple of years ago, a dozen or more companies jumped on the NASH bandwagon, pushing various kinds of hokey MoAs. NASH is a complex, multifaceted disease, so it was almost certain that most of these efforts would fail.

As you noted, ENTA's NASH drug has the same MoA as ICPT's.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today